ASTH vs. USPH: Which Stock Is the Better Value Option?

Zacks analysis identifies Astrana Health (ASTH) as a more compelling value investment than U.S. Physical Therapy (USPH) within the Medical - Outpatient and Home Healthcare sector. ASTH holds a Zacks Rank of #1 (Strong Buy) compared to USPH's #3 (Hold), indicating a stronger earnings outlook. This is further supported by ASTH's more favorable valuation metrics, including a forward P/E of 23.09 versus USPH's 31.71, and a significantly lower PEG ratio of 0.78 compared to USPH's 4.15, culminating in ASTH receiving a superior Value grade of B.

Analysis

Based on a comparative value analysis within the Medical - Outpatient and Home Healthcare sector, Astrana Health (ASTH) emerges as a more compelling opportunity than U.S. Physical Therapy (USPH). This assessment is primarily driven by ASTH's superior Zacks Rank of #1 (Strong Buy), which indicates a stronger trend of positive earnings estimate revisions compared to USPH's #3 (Hold) rating. The valuation case for ASTH is further solidified by multiple metrics; its forward P/E ratio stands at a more attractive 23.09 versus 31.71 for USPH. Critically, ASTH's PEG ratio of 0.78 suggests its stock is potentially undervalued relative to its expected earnings growth, a stark contrast to USPH's significantly higher PEG of 4.15. This quantitative advantage is also reflected in its slightly lower P/B ratio of 2.28 against USPH's 2.5, culminating in a superior Zacks Value grade of B for ASTH, while USPH receives a C.

Key Decisions for Investors

• Value-oriented investors should consider Astrana Health (ASTH) given its 'Strong Buy' rating and compelling valuation metrics, particularly its PEG ratio of 0.78, which suggests potential for price appreciation aligned with earnings growth.
• Investors holding U.S. Physical Therapy (USPH) may want to re-evaluate their position, as its 'Hold' rating is supported by a high forward P/E of 31.71 and a PEG of 4.15, indicating it is significantly more expensive than ASTH on a growth-adjusted basis.
• The core of this bullish thesis on ASTH relies on its positive earnings estimate revisions; therefore, it is critical to monitor for any changes to analyst estimates or the company's Zacks Rank, as this would be a key signal of a shifting outlook.